NCT01877083View on ClinicalTrials.gov

Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 5, 2013

Primary Completion Date

February 3, 2016

Study Completion Date

November 2, 2017

Conditions

KIF5B-RET-Positive Adenocarcinoma of the Lung

Interventions

DRUG

Lenvatinib

Starting dose of 24 mg orally, once per day

Trial Locations (23)

Unknown

Duarte

La Jolla

Whittier

Jacksonville

Canton

Cleveland

Knoxville

Dallas

Hong Kong

Shatin

Nagoya

Kashiwa

Akashi

Kobe

Natori-shi

Ōsaka-sayama

Chuo-ku

Koto-Ku

Fukuoka

National Cancer Center Hospital, Singapore

National University Hospital, Singapore

National Taiwan University Hospital, Taipei

Veterans General Hospital Taipei, Taipei

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY

NCT01877083 - Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung | Biotech Hunter | Biotech Hunter